NitroMed’s BiDil XR Will Use Elan Delivery Technology Under Recent Deal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NitroMed aims to have a regulatory and development plan for an extended-release formulation of its heart failure combo therapy BiDil (isosorbide dinitrate/hydralazine) by the middle of the year, the firm told Pharmaceutical Approvals Monthly